Talphera Inc(TLPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:00 PM ET (Korea 11/4 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.26 | Insider Own | 25.69% | Shs Outstand | 51.9M | Perf Week | -4.59% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | -5% | Insider Trans | - | Shs Float | 38.6M | Perf Month | -10.34% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.05 | Inst Own | 45.62% | Short Float | 2.76% | Perf Quarter | -22.96% |
| Income | -0.02B | P/S | - | EPS this Y | 41.18% | Inst Trans | 0.55% | Short Ratio | 6.17 | Perf Half Y | 15.18% |
| Sales | 0.00B | P/B | 3.75 | EPS next 5Y | 28.04% | ROA | -69.6% | Short Interest | 1.07M | Perf YTD | -8.77% |
| Book/sh | 0.28 | P/C | 3.16 | EPS past 3/5Y | - 48.69% | ROE | -143.36% | 52W High | -33.76% ($1.57) | Perf Year | -26.24% |
| Cash/sh | 0.33 | P/FCF | - | Sales past 3/5Y | - -65.11% | ROIC | -72.12% | 52W Low | 51.47% ($0.69) | Perf 3Y | 101.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.57% | Gross Margin | - | Volatility(W/M) | 4.24% 4.09% | Perf 5Y | -94.16% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -96.3% | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | -97.96% |
| Dividend Ex-Date | - | Quick Ratio | 4.29 | EPS Q/Q | 43.47% | Profit Margin | - | RSI (14) | 39.75 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.29 | Sales Q/Q | - | SMA20 | -2.44% ($1.07) | Beta | 0.73 | Target Price | $3.12 |
| Payout | - | Debt/Eq | 0.45 | Earnings | 2026/8/12 | SMA50 | -8.68% ($1.14) | Rel Volume | 0.47 | Prev Close | $1.01 |
| Employees | 12 | LT Debt/Eq | 0.45 | EPS/Sales Surpr. | 4% - | SMA200 | 2.8% ($1.01) | Avg Volume(3M) | 0.17M | Price | $1.04 |
| IPO | 2011/2/11 | Option/Short | Yes/Yes | Trades | 220 | Volume | 81,013 | Change | 2.97% |
A specialty pharmaceutical company developing Niyad (nafamostat formulation), an anticoagulant for patients undergoing continuous renal replacement therapy (CRRT) in the intensive care unit. Niyad is an FDA-designated drug candidate aimed at reducing bleeding risk compared with conventional heparin, and the company is currently running the Phase 3 NEPHRO CRRT clinical trial. Formerly AcelRx Pharmaceuticals, the company changed its name in 2024.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
TLPH has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +41.2% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.2%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 45.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #59 of 83 in the industry
Based on market cap of $54M.
FAQ
What kind of company is TLPH?
TLPH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TLPH?
The market cap of TLPH is approximately $54M, ranking 4,799 within its sector.
What is the 52-week high and low for TLPH?
TLPH has recorded a 52-week high of $1.57 and a low of $0.69.
